VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

B. melitensis DNA vaccine p-ialB
Vaccine Information
  • Vaccine Name: B. melitensis DNA vaccine p-ialB
  • Target Pathogen: Brucella spp.
  • Target Disease: Brucellosis
  • Vaccine Ontology ID: VO_0004397
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • IalB gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pCR3.1 expressed IalB (Commander et al., 2007).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000234
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Brucella specific IFNγ was still evident at 12 weeks post-vaccination, albeit at low concentration, indicating generation of a lasting Th1 immune response (Commander et al., 2007).
  • Efficacy: P-ialB vaccine was very promising in terms of control of Brucella challenge, as they were unable to recover viable Brucella from the spleens of 60% (three out of five) p-ialB treated mice of a study group following challenge with ∼1 × 104 CFU B. melitensis 16M per mouse. The remaining two mice showed significantly reduced Brucella loads compared to the unvaccinated (PBS and vector control) mice. If the data is considered in terms of the % of animals without detectable Brucella in their spleens (less than 10 CFU per spleen) at 15 days post-challenge, the effect of the p-ialB vaccination is judged to be equivalent to that of the Rev.1 live attenuated vaccine, with each vaccine able to ‘protect’ 60% of the test population. Moreover, a comparison of the total quantitative data available from each sample shows the Brucella load of the p-ialB and Rev.1 vaccinated animals to be significantly lower (p < 0.05, one-way ANOVA, Dunnett's post-test) than that observed for the unprotected controls (PBS or pcDNA3.1 vector control vaccinated mice). This vaccine was shown to have a protective index of greater than 2.5 (Commander et al., 2007).
References
Commander et al., 2007: Commander NJ, Spencer SA, Wren BW, MacMillan AP. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine. 2007; 25(1); 43-54. [PubMed: 17049676].